Trial Profile
Safety and Efficacy of BXCL501, a Sublingual Film Delivery of Dexmedetomidine for the Treatment of Acute Agitation in Schizophrenia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Acronyms DEX
- 17 Apr 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 17 Apr 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 22 Jul 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.